Australia’s adult stem cell company, Mesoblast Limited has announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company,

Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or ‘off-the-shelf’, adult stem cells for patients with heart attacks.

The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission. These showed that implantation of the company’s proprietary allogeneic stem cells by catheter into damaged heart muscle resulted in significant improvement in heart function and reduction in congestive heart failure.

This clinical trial will be the first to test an allogeneic stem cell product injected by catheter into heart muscle damaged by a recent heart attack. The trial will use the latest generation catheters provided through Angioblast’s ongoing relationship with the Johnson


  • Heart Attack Patient "100%" After Experimental Stem Cell Treatment
  • Stem Cell Clinical Trial for Heart Attack Patients Reaches Safety Milestone
  • Stem Cell Product Trial to Treat Heart Attack Receives FDA Clearance
  • Stem Cells to Improve Functioning of Heart in Patients Suffering from Heart Failure or Heart Attack
  • Stem Cell Test Treatment for Heart Attack Patients
  • FDA Approves Stem Cell Trial for Chronic Ischemia
  • Stem Cell Therapy Improves Heart Function After Heart Attack (Myocardial Infarction)
  • Stem Cell Could Prevent Heart Attack by Repairing Damaged Heart Muscles
  • Bio-heart Trial Using Myocell Myoblast Cells Proves Successful
  • Stem Cell Therapy Successfully Treats Heart Attack in Animals; Patients Enrolled for Phase 1 Clinical Trial